Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

MiMedx Group Inc

Healthcare US MDXG

3.71USD
0.01(0.27%)

Last update at 2026-06-09T20:00:00Z

Day Range

3.653.75
LowHigh

52 Week Range

5.479.27
LowHigh

Fundamentals

  • Previous Close 3.70
  • Market Cap1108.51M
  • Volume1132784
  • P/E Ratio15.02
  • Dividend Yield-%
  • EBITDA53.98M
  • Revenue TTM334.51M
  • Revenue Per Share TTM2.69
  • Gross Profit TTM 219.53M
  • Diluted EPS TTM0.50

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -29.99100M -10.03800M -25.58500M -3.39700M -3.39700M
Minority interest - - - - -
Net income -30.19700M -10.28500M -25.58000M -29.97900M -29.97900M
Selling general administrative 208.79M 198.36M 181.02M 252.63M 252.63M
Selling and marketing expenses - - - - -
Gross profit 219.53M 215.33M 256.17M 322.73M 322.73M
Reconciled depreciation 4.05M 5.18M 6.86M 7.58M 6.92M
Ebit -24.97100M -5.00500M -20.71400M -3.92400M -3.92400M
Ebitda -20.92900M 0.18M -12.68300M 2.99M 2.99M
Depreciation and amortization 4.04M 5.18M 8.03M 6.92M 6.92M
Non operating income net other - -0.02300M -8.20400M 0.28M 0.53M
Operating income -24.97100M -5.00500M -20.71400M -3.92400M -3.92400M
Other operating expenses 292.81M 263.60M 319.97M 363.04M 363.04M
Interest expense 5.02M 4.98M -4.70800M 0.00000M 0.00000M
Tax provision 0.21M 0.25M -12.25900M -0.00500M 26.58M
Interest income - - - - -
Net interest income -5.01600M -4.98000M -7.94100M -4.70800M -
Extraordinary items - - - - -
Non recurring - 0.05M 1.03M 0.45M -
Other items - - - - -
Income tax expense 0.21M 0.25M -0.00500M 26.58M 26.58M
Total revenue 267.84M 258.62M 299.25M 359.11M 359.11M
Total operating expenses 244.50M 220.31M 276.89M 326.65M 326.65M
Cost of revenue 48.32M 43.28M 43.08M 36.39M 36.39M
Total other income expense net -5.02000M -5.03300M -4.87100M 0.53M 0.53M
Discontinued operations - - - - -
Net income from continuing ops -30.19700M -10.28500M -49.28400M -25.58000M -29.97900M
Net income applicable to common shares -36.77700M -10.28500M -83.32800M -25.58000M -29.97900M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 239.05M 171.43M 187.93M 167.17M 122.84M
Intangible assets 5.26M 5.85M 5.38M 7.78M 9.61M
Earning assets - - - - -
Other current assets 1.75M 2.63M 2.81M 6.06M 5.82M
Total liab 96.33M 189.42M 187.85M 132.77M 73.19M
Total stockholder equity 142.72M -17.98800M 0.08M 34.40M 49.66M
Deferred long term liab - - - - -
Other current liab 36.96M 34.71M 34.97M 1.40M 56.68M
Common stock 0.15M 0.11M 0.11M 0.11M 0.11M
Capital stock 0.15M 0.11M 92.61M 91.68M 0.11M
Retained earnings -133.67800M -17.98800M -161.70900M -102.14000M -76.56000M
Other liab - 2.33M 4.87M 3.75M 0.62M
Good will 19.44M 19.98M 19.98M 19.98M 19.98M
Other assets - 0.15M 0.19M 0.38M 0.44M
Cash 82.00M 65.95M 87.08M 69.07M 45.12M
Cash and equivalents - - - - -
Total current liabilities 46.01M 43.56M 42.36M 67.32M 71.55M
Current deferred revenue -1.54800M - - 53.46M -
Net debt -33.90100M -17.35600M -38.95600M -3.41300M -45.11800M
Short term debt 1.55M - - 3.75M 3.75M
Short long term debt - - - - 3.75M
Short long term debt total 48.10M 48.59M 48.13M 65.66M 65.66M
Other stockholder equity 276.25M -92.60800M 161.68M 136.43M 144.69M
Property plant equipment - 11.26M 13.86M 11.44M 15.72M
Total current assets 164.26M 134.20M 148.52M 123.25M 74.05M
Long term investments - - - - -
Net tangible assets - -43.81600M -25.27700M 91.42M 6.64M
Short term investments - - - - -
Net receivables 53.87M 43.79M 41.10M 32.34M 0.45M
Long term debt 48.10M 48.59M 48.13M 47.70M 61.91M
Inventory 21.02M 13.18M 11.39M 9.10M 15.99M
Accounts payable 9.05M 8.85M 7.38M 8.71M 14.86M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -239.04700M - -92.49400M -91.56800M -18.58700M
Additional paid in capital - - - - -
Common stock total equity - - 0.11M 0.11M 0.11M
Preferred stock total equity - - - - -
Retained earnings total equity - - -161.70900M -151.42400M -102.14000M
Treasury stock - - -4.01700M -7.44900M -10.80600M
Accumulated amortization - - - - -
Non currrent assets other 0.20M 0.15M 0.19M 0.44M 1.79M
Deferred long term asset charges - - - - -
Non current assets total 74.79M 37.23M 39.41M 43.92M 48.80M
Capital lease obligations - - - - -
Long term debt total - - - - 61.91M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -2.66000M -3.39500M -4.55500M 2.72M 0.78M
Change to liabilities 1.05M -0.32600M 0.20M -8.94500M 23.82M
Total cashflows from investing activities -2.66000M -3.39500M -4.55500M 0.50M -9.22000M
Net borrowings -0.04100M -0.03800M -29.04600M 64.22M -0.00300M
Total cash from financing activities -0.58000M -3.35200M 62.86M -8.93400M -8.93400M
Change to operating activities -2.77700M -17.09500M -1.48600M -10.26200M 18.34M
Net income -30.19700M -10.28500M -25.58000M -29.97900M -29.97900M
Change in cash -21.13300M -8.72900M 23.95M 17.64M 17.64M
Begin period cash flow 87.08M 95.81M 45.12M 27.48M 27.48M
End period cash flow 65.95M 87.08M 69.07M 45.12M 45.12M
Total cash from operating activities -17.89300M -1.98200M -39.41200M 35.80M 35.80M
Issuance of capital stock 0.00000M 0.00000M 100.00M - -
Depreciation 4.05M 5.18M 7.58M 6.92M 6.92M
Other cashflows from investing activities - 0.07M -0.32700M -0.46600M -0.57900M
Dividends paid -0.65100M - -100.00000M - -
Change to inventory -1.79400M -1.02800M 6.88M -6.51900M -6.51900M
Change to account receivables -5.55000M -4.93000M -10.93800M 16.45M -0.19000M
Sale purchase of stock -1.19000M -4.75100M -1.47400M -12.48600M -4.01700M
Other cashflows from financing activities 0.65M 1.44M 66.21M 3.56M 36.17M
Change to netincome 16.82M 16.14M 22.13M 11.92M 42.39M
Capital expenditures 2.68M 3.47M 2.22M 10.03M 9.42M
Change receivables - -4.93000M -3.09600M -10.93800M -
Cash flows other operating - 10.42M -8.09900M -21.76500M -0.97400M
Exchange rate changes - - - - -
Cash and cash equivalents changes - -8.72900M 26.74M 23.95M 17.64M
Change in working capital -9.02900M -14.07700M -20.05300M 18.60M -0.43500M
Stock based compensation 12.67M 14.76M 12.06M 14.77M -
Other non cash items 4.62M 2.12M -15.00400M -0.05300M 14.71M
Free cash flow -20.57700M -5.45200M -41.63000M 25.77M 25.77M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MDXG
MiMedx Group Inc		 0.01 0.27% 3.71 15.02 20.12 2.94 6.64 2.84 22.54
NVO
Novo Nordisk A/S		 1.17 2.85% 42.19 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.35 0.85% 41.60 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 2.81 0.63% 445.77 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 4.84 0.79% 616.18 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.

MiMedx Group Inc

1775 West Oak Commons Court, NE, Marietta, GA, United States, 30062

Key Executives

Name Title Year Born
Mr. K. Todd Newton Interim CEO & Director 1963
Mr. Peter Martin Carlson CPA Chief Financial Officer 1964
Mr. William F. Hulse IV Gen. Counsel & Chief Admin. Officer 1974
Dr. Rohit Kashyap Ph.D. Pres of Wound Care & Surgical 1971
Dr. Robert Benjamin Stein M.D., Ph.D. Pres of Regenerative Medicine & Biologics Innovation 1951
Mr. Scott M. Turner Sr. VP of Operations & Procurement 1965
Mr. William L. Phelan Sr. VP & Chief Accounting Officer NA
Mr. Matthew M. Notarianni Head of Investor Relations NA
Mr. Mark P. Graves Sr. VP & Chief Compliance Officer 1966
Hilary Dixon VP of Investor Relations & Corp. Strategic Communications NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions